Shortly after, a commercial anti-CD133 polyclonal antibody conjugated to paclitaxel loaded nanoparticles exhibited anti-tumor effects in liver cancer in vitro and in vivo models [142]. This evidence concerns the gene PROM1 and liver cancer.